|
Name |
Phomopsidin
|
Molecular Formula | C21H30O3 | |
IUPAC Name* |
(2E,4E)-5-[(1S,2R,4aS,5S,8S,8aS)-2-[(E)-but-2-en-2-yl]-5-hydroxy-3,8-dimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]penta-2,4-dienoic acid
|
|
SMILES |
C/C=C(\C)/[C@H]1[C@H]([C@@H]2[C@H](CC[C@@H]([C@@H]2C=C1C)O)C)/C=C/C=C/C(=O)O
|
|
InChI |
InChI=1S/C21H30O3/c1-5-13(2)20-15(4)12-17-18(22)11-10-14(3)21(17)16(20)8-6-7-9-19(23)24/h5-9,12,14,16-18,20-22H,10-11H2,1-4H3,(H,23,24)/b8-6+,9-7+,13-5+/t14-,16+,17-,18-,20+,21-/m0/s1
|
|
InChIKey |
KNDPLJZJPQWOMQ-FDTXVGEPSA-N
|
|
Synonyms |
Phomopsidin; SCHEMBL3404620; 199173-60-9; ZINC31166452; NCGC00380736-01; (2E,4E)-5-[(1S,2R,4aS,5S,8S,8aS)-2-[(E)-but-2-en-2-yl]-5-hydroxy-3,8-dimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]penta-2,4-dienoic acid; NCGC00380736-01_C21H30O3_(2E,4E)-5-{(1S,2R,4aS,5S,8S,8aS)-2-[(2E)-2-Buten-2-yl]-5-hydroxy-3,8-dimethyl-1,2,4a,5,6,7,8,8a-octahydro-1-naphthalenyl}-2,4-pentadienoic acid
|
|
CAS | NA | |
PubChem CID | 10381991 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 330.5 | ALogp: | 4.2 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 57.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 24 | QED Weighted: | 0.438 |
Caco-2 Permeability: | -4.985 | MDCK Permeability: | 0.00002840 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.978 |
Human Intestinal Absorption (HIA): | 0.909 | 20% Bioavailability (F20%): | 0.044 |
30% Bioavailability (F30%): | 0.009 |
Blood-Brain-Barrier Penetration (BBB): | 0.444 | Plasma Protein Binding (PPB): | 96.54% |
Volume Distribution (VD): | 0.395 | Fu: | 3.62% |
CYP1A2-inhibitor: | 0.041 | CYP1A2-substrate: | 0.097 |
CYP2C19-inhibitor: | 0.015 | CYP2C19-substrate: | 0.807 |
CYP2C9-inhibitor: | 0.015 | CYP2C9-substrate: | 0.863 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.127 |
CYP3A4-inhibitor: | 0.046 | CYP3A4-substrate: | 0.307 |
Clearance (CL): | 5.323 | Half-life (T1/2): | 0.835 |
hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.665 |
Drug-inuced Liver Injury (DILI): | 0.222 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.783 | Maximum Recommended Daily Dose: | 0.881 |
Skin Sensitization: | 0.866 | Carcinogencity: | 0.118 |
Eye Corrosion: | 0.315 | Eye Irritation: | 0.101 |
Respiratory Toxicity: | 0.965 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003167 | 0.355 | D0FG6M | 0.238 | ||||
ENC004701 | 0.345 | D0E9KA | 0.235 | ||||
ENC003807 | 0.343 | D00DKK | 0.228 | ||||
ENC003585 | 0.343 | D02DGU | 0.228 | ||||
ENC006079 | 0.333 | D0G3PI | 0.228 | ||||
ENC006077 | 0.313 | D04SFH | 0.220 | ||||
ENC006078 | 0.306 | D0N3NO | 0.209 | ||||
ENC004696 | 0.297 | D05QDC | 0.206 | ||||
ENC003166 | 0.296 | D0X7XG | 0.197 | ||||
ENC004112 | 0.293 | D0W2EK | 0.195 |